in

ANI Pharma (NASDAQ:ANIP) – ANI Pharma’s Purified Cortrophin Gel Application Under FDA Review

ANI Pharma (NASDAQ:ANIP) - ANI Pharma's Purified Cortrophin Gel Application Under FDA Review

  • The FDA has accepted ANI Pharmaceuticals Inc’s (NASDAQ: ANIP) supplemental marketing application for Purified Cortrophin Gel.
  • The application seeks approval for multiple indications, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.
  • Prescription Drug User Fee Act’s target action date is October 29.
  • Related content: Benzinga’s Full FDA Calendar.
  • Price Action: ANIP shares are 11.20% at $30.46 during the premarket session on the last check Tuesday.